Status:
COMPLETED
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
Lead Sponsor:
Bayer
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
18-71 years
Phase:
PHASE3
Brief Summary
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
Detailed Description
This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Completion of the 12-week treatment period of the predecessor Schering study 97218/300180
- Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient
- Negative pregnancy test for females
Exclusion
- Any condition during 12-week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the follow-up safety surveillance study
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00185315
Start Date
February 1 2000
End Date
August 1 2005
Last Update
April 20 2010
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Brussels, Belgium, 1070
2
Leuven, Belgium, 3000
3
Clamart, France, 92141
4
Grenoble, France, 38043